Hormonal therapy for metastatic prostate cancer / 中国癌症杂志

ABSTRACT

The development and progress of prostate cancer is hormone dependent. Currently, hormonal treatment remains the most important treatment modality for alleviating the symptoms caused by metastatic prostate cancer. Hormonal therapy for prostate cancer includes orchidectomy(with or without adrenectomy) or drug therapy. The most commonly prescribed hormonal therapy medication for prostate cancer is LHRH agonists. Whether total androgen block using LHRH agonist and androgen blocking agents (combined androgen blockade) is more effective than single agent LHRH agonist in the treatment of late stage prostate cancer is unknown. Second line hormonal treatment is effective for selected patients with hormone refractory prostate cancer (HRPC). Although certain chemotherapeutic agents such as taxol has shown its efficacy for prostate cancer, second line chemotherapy should be utilized prior to chemotherapy for HRPC.